An interventional study of Dexamethasone and Targeted blood pressure management in Lung Cancer, Surgery and Blood Pressure Management, sponsored by Peking University First Hospital. Recruiting at 1 site in China. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-07-31.
Sponsored by Peking University First Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing dexamethasone in Lung Neoplasms — 4 open to participants now, 4 under way, 1 of them phase 3. Dexamethasone · Lung Neoplasms.
Among the 10 studies testing dexamethasone in Lung Neoplasms, this one has the largest planned enrollment, is the only one that started in 2020, is the only one with no phase, and was the 7th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →4 of the 10 studies testing dexamethasone in Lung Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
Brown University · Sites in United States
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark
Ages 18+
David Palma · Sites in Canada
Ages 18+
By country, each count listing its studies:
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 50 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 3 · Phase 4 3
First in 2004; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,988 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 99 across the 10 interventional studies. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 10 most frequent:
Peking University First Hospital is the lead sponsor of 393 studies on the registry; 188 are open to participants now.
Peking University First Hospital has 5 studies filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies testing dexamethasone in Lung Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04209218Peking University First HospitalIntraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery | 2026-12 |
| NCT06974604Brown UniversityPreventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM | 2027-05-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing dexamethasone in Lung Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Surgery is the front-line therapy for non-small cell lung cancer (NSCLC) but postoperative complications remains high and patients' long-term outcome is still challenging. In addition to surgery, anesthetic management particularly intraoperative blood pressure management and use of dexamethasone may affect patients' early and long-term outcomes after surgery for NSCLC. This study aims to investigate the impact of intraoperative blood pressure management and dexamethasone administration on early and long-term outcomes in patients undergoing surgery for lung cancer.
Surgical resection is the main treatment for patients with non-small cell lung cancer (NSCLC) and continuous efforts have been made to evolve surgical strategies and techniques. It has been now been realized that perioperative period is characterized with profound changes and anesthesia management may also affect outcomes of patients after cancer surgery.
Even under well controlled conditions, blood pressure fluctuation frequently occurs during anesthesia and surgery. In previous studies, intraoperative hypotension was associated with increased risk of organ injuries (such as delirium, acute kidney injury, myocardial injury, and stroke) and higher 1-year mortality. Unpublished data showed that intraoperative hypotension was also associated with shortened long-term survival in patients after lung cancer surgery. In a recent trial, individualized intraoperative blood pressure management which avoided intraoperative hypotension decreased the incidence of postoperative organ injury when compared with routine practice. Avoiding intraoperative hypotension may also prolong survival after lung cancer surgery. However, evidences are lacking regarding this topic.
Dexamethasone is frequently used for prevention of postoperative nausea and vomiting. Studies showed that a single low-dose dexamethasone has anti-inflammatory effect and can regulate immune function. It has been shown that perioperative dexamethasone can improve analgesia after surgery. In retrospective studies, perioperative low-dose dexamethasone was associated with less wound infection and improved long-term survival in patients after surgeries for pancreatic and lung cancer. It is hypothesized that intraoperative dexamethasone may reduce postoperative complications and improve long-term survival after lung cancer surgery. Interventional studies are required to confirm this hypothesis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood pressure is maintained according to routine practice. Placebo (normal saline 2 ml) is administered before anesthesia induction.
Drug: Placebo · Other: Routine blood presure management
Blood pressure is maintained according to routine practice. Dexamethasone (10 mg/2 ml) ia administered before anesthesia induction.
Drug: Dexamethasone · Other: Routine blood presure management
Blood pressure is maintained within ±10% from baseline. Placebo (normal saline 2 ml) is administered before anesthesia induction.
Other: Targeted blood pressure management · Drug: Placebo
Blood pressure is maintained within ±10% from baseline. Dexamethasone (10 mg/2 ml) is administered before anesthesia induction.
Drug: Dexamethasone · Other: Targeted blood pressure management
Dexamethasone (10 mg/2 ml) is administered before anesthesia induction.
Also known as: Glucocorticoids
Blood pressure is maintained within ±10% from baseline.
Placebo (2 ml normal saline) is administered before anesthesia induction.
Also known as: Normal saline
Blood pressure is maintained according to routine practice.
Overall survival after surgery
Overall survival after surgery
Time frame: Up to 5 years after surgery
Incidence of organ injury and complications within 5 days after surgery (sub-study).
Organ injury includes delirium, acute kidney injury and myocardial injury. Postoperative complications are generally defined as newly occurred medical conditions that are harmful to patients' recovery and required therapeutic intervention, i.e., grade II or above on the Clavien-Dindo classification.
Time frame: Up to 5 days after surgery.
Recurrence-free survival after surgery
Recurrence-free survival after surgery
Time frame: Up to 5 years after surgery
Cancer-specific survival after surgery
Cancer-specific survival after surgery
Time frame: Up to 5 years after surgery
Event-free survival after surgery
Event-free survival after surgery
Time frame: Up to 5 years after surgery
Rate of intensive care unit (ICU) admission after surgery (sub-study)
Rate of ICU admission after surgery
Time frame: During the day of surgery
Rate of ICU admission with endotracheal intubation after surgery (sub-study)
Rate of ICU admission with endotracheal intubation after surgery
Time frame: During the day of surgery
Duration of mechanical ventilation in ICU after surgery (sub-study)
Duration of mechanical ventilation in ICU after surgery
Time frame: Up to 30 days after surgery
Length of stay in ICU after surgery (sub-study)
Length of stay in ICU after surgery
Time frame: Up to 30 days after surgery
Incidence of organ injury within 5 days after surgery (sub-study)
Organ injury includes delirium, acute kidney injury and myocardial injury. Delirium is assessed with the 3-minute diagnostic assessment for CAM-defined delirium (3D-CAM). Acute kidney injury is diagnosed according to the KDIGO (Kidney Disease: Improving Global Outcomes) criteria. Myocardial injury is diagnosed according to the serum cardiac troponin I level (higher than upper normal limit of the hospital's clinical laboratory).
Time frame: Up to 5 days after surgery
Incidence of complications within 30 days after surgery (sub-study)
Postoperative complications are defined as new-onset medical events that are harmful to patients' recovery and required therapeutic intervention, i.e., grade II or above on the Clavien-Dindo classification.
Time frame: Up to 30 days after surgery
Length of stay in hospital after surgery (sub-study)
Length of stay in hospital after surgery
Time frame: Up to 30 days after surgery
Rate of 30-day all-cause mortality (sub-study)
Death due to any cause within 30 days after surgery
Time frame: Up to 30 days after surgery
Overall survival after surgery in cancer patients
Overall survival after surgery in cancer patients
Time frame: Up to 5 years after surgery
Recurrence-free survival after surgery in cancer patients
Recurrence-free survival after surgery in cancer patients
Time frame: Up to 5 years after surgery
Cancer-specific survival after surgery in cancer patients
Cancer-specific survival after surgery in cancer patients
Time frame: Up to 5 years after surgery
Event-free survival after surgery in cancer patients
Event-free survival after surgery in cancer patients
Time frame: Up to 5 years after surgery
30-item quality of life in 1-, 2-, and 3-year survivors
Quality of life is assessed with the 30-item Core Quality of Life Questionnaire (QLQ-C30), which assess functioning and symptom scales. The score of each scale ranges from 0 to 100, with higher score indicating better function or worse symptom.
Time frame: At the end of the 1st, 2nd, and 3rd year after surgery
13-item quality of life in 1-, 2-, and 3-year survivors
Quality of life is assessed with the 13-item Quality of Life Questionnaire-Lung Cancer Module (QLQ LC-13), which assess symptom scales. The score of each scale ranges from 0 to 100, with higher score indicating worse symptom. The QLQ LC-13 is a supplementary questionnaire module to be employed in conjunction with the QLQ-C30.
Time frame: At the end of the 1st, 2nd, and 3rd year after surgery
Pain score within 3 days after surgery (sub-study)
Pain score is assessed with the Numeric Rating Scale, an 11-point scale where 0=no pain and 10=the worst pain.
Time frame: Up to 3 days after surgery
Subjective sleep quality score within 3 days after surgery (sub-study)
Subjective sleep quality is assessed with the Numeric Rating Scale, an 11-point scale where 0=the best sleep and 10=the worst sleep.
Time frame: Up to 3 days after surgery
Plan to share: No
Started Apr 2020 (actual). Primary completion is estimated for Dec 2026, 80 months after the start.
Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 80 months is above that.
Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone
Peking University First Hospital →